- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 06.03. | Alnylam bets on Tenaya RNAi tech, and other licensing news | ||
| 05.03. | Lilly unveils employer scheme for weight-loss drug Zepbound | ||
| 05.03. | PepGen slumps as FDA places hold on lead drug | ||
| 05.03. | Can GLP-1 drugs help tackle addiction? | ||
| 05.03. | Hansa closes on FDA verdict for transplant drug imlifidase | ||
| 05.03. | Welsh firm Antiverse raises funds for AI antibody platform | ||
| 04.03. | Five projects share £100m UK-US Cancer Grand Challenges fund | ||
| 04.03. | Moderna agrees $950m settlement of mRNA jab litigation | ||
| 04.03. | Cancer risk scuppers Kyowa Kirin's autoimmune disease drug | ||
| 04.03. | FDA ramps up its pushback against compounded GLP-1s | ||
| 04.03. | UK puts £50m behind expanded clinical trials drive | ||
| 03.03. | 'Dismal' survival demands change in bile duct cancer therapy | ||
| 03.03. | Quell takes new Treg into clinic after transplant study halt | ||
| 03.03. | Ascendis scores FDA approval for weekly dwarfism drug | ||
| 03.03. | CMS extends deadline for MFN pricing pilot scheme | ||
| 02.03. | United's PAH drug clears phase 3 trial, setting up filings | ||
| 02.03. | New FDA knockback hits uniQure and Huntington patients hard | ||
| 02.03. | Novo Nordisk plans €432m investment in Irish GLP-1 plant | ||
| 02.03. | After phase 3 clean sweep, Roche plans oral BTK filing in MS | ||
| 02.03. | CHMP backs Ipsen drug for childhood brain cancer | ||
| 02.03. | New biotech Atrium born out of Novartis/Avidity marriage | ||
| 27.02. | NHS "isn't delivering equitable care for rare diseases" | ||
| 27.02. | Moderna closes on EU approval for combined flu/COVID jab | ||
| 27.02. | Boehringer gets FDA's second 'national priority' approval | ||
| 27.02. | US lawmakers take FDA to task over rare diseases record |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.